This composite flow cytometric panel illustrates the bone marrow of a newly diagnosed primary plasma cell leukemia patient demonstrating CD38 +, λ-a-restricted, CD20-plasma cells.

BPDCN is an aggressive type of blood cancer that originates from plasmacytoid dendritic cells (pDCs), a component ... according to the Leukemia and Lymphoma Society (LLS). BPDCN is a rare ...

Neoplastic cell morphology in peripheral blood (A ... and immunohistochemistry expression of Ki67 of tumor cells (C2; immunoperoxidase, 400×). Universidade Federal de São Paulo (UNIFESP), São Paulo, ...

Researchers from Tokyo Metropolitan University have found that the motion of unlabeled cells can be used to tell whether they ...

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive ...

A team of researchers from the University of Chicago, in collaboration with researchers from the University of Pittsburgh, ...

Plasma cell leukemia (PCL) is a rare disease that may present de novoor secondary to plasma cell myeloma. Advanced disease and extramedullary involvement are common clinical features at presentation.

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...